2 / 32
KEYTRUDA is indicated as
monotherapy for the treatment
of unresectable or metastatic
melanoma in adults.
¹
Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme
(Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. ONCO-1130195-0277. First issued June 2017. MSDONC1065.
Before prescribing, please review the Product Information.
Product Information is available at
www.msdinfo.com.au/keytrudapiPBS Information:
Authority required (STREAMLINED) for treatment of metastatic melanoma.
Refer to PBS Schedule for full authority information.
GIVE YOUR PATIENTS A KEY FOR
FIRST-LINE TREATMENT OF
METASTATIC MELANOMA